Kiadis abandons lead PhIII program, shifts focus to natural killer cells
Kiadis Pharma announced that it is shifting focus to natural killer cells — and is itself killing off the long-running but deeply troubled Phase III ATIR program that has largely defined the company. It will cut approximately half of its workforce.
Kiadis acquired CytoSen Therapeutics and its natural killer (NK) technology in April. The Netherlands-based Kiadis had been developing a T cell therapy called ATIR101 that was then in Phase III for blood cancer patients, namely acute myeloid leukemia. At the time, it seemed that the Dutch biotech would pair its T cell therapy with the US-based NKs in an intercontinental, multi-cellular effort with implications for transplants and oncology.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.